{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:41:49Z","timestamp":1792428109088,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.leukres.2026.108303","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:36:18Z","timestamp":1788478578000},"page":"108303","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["From standardization to precision medicine: Evolution of European Leukemianet recommendations in Philadelphia-negative myeloproliferative neoplasms"],"prefix":"10.1016","volume":"170","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5687-8531","authenticated-orcid":false,"given":"Rafiye","family":"Ciftciler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim Celalettin","family":"Haznedaroglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.leukres.2026.108303_bib1","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet","volume":"29","author":"Barbui","year":"2011","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.leukres.2026.108303_bib2","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.leukres.2026.108303_bib3","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1182\/blood-2016-10-695957","article-title":"Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms","volume":"129","author":"Rumi","year":"2017","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.leukres.2026.108303_bib4","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1182\/blood-2008-09-176818","article-title":"Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference","volume":"113","author":"Barosi","year":"2009","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.leukres.2026.108303_bib5","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1182\/blood.2020008109","article-title":"The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms","volume":"137","author":"Hasselbalch","year":"2021","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.leukres.2026.108303_bib6","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1182\/blood-2013-01-478891","article-title":"Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project","volume":"121","author":"Barosi","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2026.108303_bib7","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","article-title":"MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis","volume":"36","author":"Guglielmelli","year":"2018","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.leukres.2026.108303_bib8","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.mayocp.2017.06.002","article-title":"Genetic risk assessment in myeloproliferative neoplasms","volume":"92","author":"Tefferi","year":"2017","journal-title":"Mayo Clin. Proc."},{"issue":"8","key":"10.1016\/j.leukres.2026.108303_bib9","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1038\/s41375-025-02646-y","article-title":"Impact of ELN clinical signs and symptoms on the thrombotic risk in polycythemia vera patients treated with front-line hydroxyurea","volume":"39","author":"Palandri","year":"2025","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.leukres.2026.108303_bib10","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/ajh.25303","article-title":"Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management","volume":"94","author":"Tefferi","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"12","key":"10.1016\/j.leukres.2026.108303_bib11","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/ajh.22210","article-title":"Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management","volume":"86","author":"Tefferi","year":"2011","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2026.108303_bib12","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/asheducation-2010.1.129","article-title":"Rethinking disease definitions and therapeutic strategies in essential thrombocythemia and polycythemia vera","volume":"2010","author":"Harrison","year":"2010","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"issue":"1","key":"10.1016\/j.leukres.2026.108303_bib13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41408-025-01235-7","article-title":"Evolution of WHO diagnostic criteria in \"Classical Myeloproliferative Neoplasms\" compared with the International Consensus Classification","volume":"15","author":"Thiele","year":"2025","journal-title":"Blood Cancer J."},{"issue":"8","key":"10.1016\/j.leukres.2026.108303_bib14","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","article-title":"Revised response criteria for myelofibrosis: international working group-myeloproliferative neoplasms research and treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report","volume":"122","author":"Tefferi","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2026.108303_bib15","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.leukres.2009.01.035","article-title":"The myelofibrosis symptom assessment form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis","volume":"33","author":"Mesa","year":"2009","journal-title":"Leuk. Res."},{"issue":"5","key":"10.1016\/j.leukres.2026.108303_bib16","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1182\/blood-2006-03-009746","article-title":"International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)","volume":"108","author":"Tefferi","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2026.108303_bib17","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/jamaoncol.2015.89","article-title":"Myeloproliferative neoplasms: a contemporary review","volume":"1","author":"Tefferi","year":"2015","journal-title":"JAMA Oncol."},{"issue":"5","key":"10.1016\/j.leukres.2026.108303_bib18","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1080\/10428194.2018.1537490","article-title":"Mutations and prognosis in myeloproliferative neoplasms","volume":"60","author":"Tefferi","year":"2019","journal-title":"Leuk. & Lymphoma"},{"issue":"1","key":"10.1016\/j.leukres.2026.108303_bib19","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13045-021-01116-z","article-title":"Molecular pathogenesis of the myeloproliferative neoplasms","volume":"14","author":"Greenfield","year":"2021","journal-title":"J. Hematol. & Oncol."},{"issue":"20","key":"10.1016\/j.leukres.2026.108303_bib20","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2026.108303_bib21","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"New. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.leukres.2026.108303_bib22","doi-asserted-by":"crossref","first-page":"5835","DOI":"10.1182\/bloodadvances.2023010151","article-title":"Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis","volume":"7","author":"Oh","year":"2023","journal-title":"Blood Adv."},{"issue":"9","key":"10.1016\/j.leukres.2026.108303_bib23","doi-asserted-by":"crossref","first-page":"10612","DOI":"10.1002\/cam4.5799","article-title":"Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies","volume":"12","author":"Mesa","year":"2023","journal-title":"Cancer Med."},{"issue":"10","key":"10.1016\/j.leukres.2026.108303_bib24","doi-asserted-by":"crossref","first-page":"e729","DOI":"10.1016\/S2352-3026(24)00212-6","article-title":"Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"11","author":"Harrison","year":"2024","journal-title":"Lancet Haematol."},{"issue":"1","key":"10.1016\/j.leukres.2026.108303_bib25","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ajh.26050","article-title":"Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management","volume":"96","author":"Tefferi","year":"2021","journal-title":"Am. J. Hematol."},{"issue":"7","key":"10.1016\/j.leukres.2026.108303_bib26","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","article-title":"GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.leukres.2026.108303_bib27","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/s41408-024-01169-6","article-title":"Thrombosis in myeloproliferative neoplasms: a viewpoint on its impact on myelofibrosis, mortality, and solid tumors","volume":"14","author":"Barbui","year":"2024","journal-title":"Blood Cancer J."},{"issue":"15","key":"10.1016\/j.leukres.2026.108303_bib28","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"New. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.leukres.2026.108303_bib29","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/ajh.26857","article-title":"Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Tefferi","year":"2023","journal-title":"Am. J. Hematol."},{"issue":"9","key":"10.1016\/j.leukres.2026.108303_bib30","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/ajh.27002","article-title":"Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management","volume":"98","author":"Tefferi","year":"2023","journal-title":"Am. J. Hematol."},{"issue":"17","key":"10.1016\/j.leukres.2026.108303_bib31","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.1182\/bloodadvances.2022007201","article-title":"Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs","volume":"6","author":"Sobas","year":"2022","journal-title":"Blood Adv."},{"issue":"6","key":"10.1016\/j.leukres.2026.108303_bib32","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1177\/10781552221082293","article-title":"Management of myeloproliferative neoplasms (MPNs)","volume":"28","author":"Nurgat","year":"2022","journal-title":"J. Oncol. Pharm. Pract. Off. Publ. Int. Soc. Oncol. Pharm. Pract."},{"issue":"5","key":"10.1016\/j.leukres.2026.108303_bib33","doi-asserted-by":"crossref","first-page":"e262","DOI":"10.1016\/j.clml.2024.12.013","article-title":"A review of real-world experience with ruxolitinib for myelofibrosis","volume":"25","author":"Al-Ali","year":"2025","journal-title":"Clin. Lymphoma Myeloma & Leuk."},{"issue":"12","key":"10.1016\/j.leukres.2026.108303_bib34","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1007\/s00277-023-05458-1","article-title":"Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were na\u00efve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial","volume":"102","author":"Koschmieder","year":"2023","journal-title":"Ann. Hematol."},{"issue":"4","key":"10.1016\/j.leukres.2026.108303_bib35","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/ejh.70005","article-title":"Final results from a large, non-interventional, phase 4 study of ruxolitinib for the treatment of myelofibrosis in clinical routine","volume":"115","author":"Koschmieder","year":"2025","journal-title":"Eur. J. Haematol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626001475?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626001475?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:07:15Z","timestamp":1792426035000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212626001475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":35,"alternative-id":["S0145212626001475"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108303","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From standardization to precision medicine: Evolution of European Leukemianet recommendations in Philadelphia-negative myeloproliferative neoplasms","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108303","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108303"}}